BioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome

BioMarin Pharmaceutical (BMRN) reported a $283M Q3 IPR&D expense, reducing GAAP and non-GAAP EPS by $1.50. Non-GAAP EPS is estimated at $1.25. The expense impacts financial results for the quarter.

BIOMARIN PHARMACEUTICAL INC (BMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition Estimated Financial Impact of the Alesta Acquisition In connection with its acquisition of Alesta Therapeutics B.V. (Alesta), a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid),

BioMarin Pharmaceutical (BMRN) presented five-year data for POMBILITI + OPFOLDA in LOPD patients at the WMS Congress. The study showed mixed results on walking distance and lung function. No new safety concerns were identified. The company also shared positive Phase 1/2 data for nivudirsen in DMD. BMRN shares traded down 1.35% to $57.65.

BioMarin Pharmaceutical (BMRN) presented five-year data on POMBILITI and OPFOLDA for late-onset Pompe disease at the World Muscle Society Congress. The study showed mixed results, with adverse events in 51.2% of participants. The company also shared Phase 1/2 data on nivudirsen for Duchenne muscular dystrophy, indicating it was generally well tolerated. POMBILITI and OPFOLDA are approved for certain adult patients with late-onset Pompe disease.

BioMarin (BMRN) presented five-year data for POMBILITI + OPFOLDA in late-onset Pompe disease at the World Muscle Society Congress. The study showed durable motor function and pulmonary stabilization. No new safety signals were identified. Additionally, BioMarin shared positive Phase 1/2 data for nivudirsen (BMN 351) in Duchenne muscular dystrophy, showing favorable tolerability and positive dystrophin expression.

Ascendis Pharma (ASND) and BioMarin (BMRN) settled a patent dispute, with ASND paying BMRN royalties on Yuviwel sales. ASND rose 6% and BMRN 1%. Analysts adjusted targets but kept ratings unchanged, citing legal clarity and growth prospects.